ArticleBMC cancer2019
Development of a miRNA-seq based prognostic signature in lung adenocarcinoma.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Liquid biopsy diagnostics for non-small cell lung cancer via elucidation of tRNA signatures.Communications medicine · 2025Article
- Mechanistic studies ofFrontiers in oncology · 2025Article
- A Four-Gene Autophagy-Related Prognostic Model Signature and Its Association With Immune Phenotype in Lung Squamous Cell Carcinoma.Cancer reports (Hoboken, N.J.) · 2024Article
- Insight into the Role of the miR-584 Family in Human Cancers.International journal of molecular sciences · 2024Review
- Obese Mouse Fat Cell-derived Extracellular Vesicles Transport miR-99a-5p to Mitigate the Proliferation and Migration of Non-small Cell Lung Cancer Cells.Combinatorial chemistry & high throughput screening · 2024Article
- Article
- Analysis and Validation of the Prognosis ability of the M7GRelated miRNAs in Lung Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- MiRNA and Potential Prognostic Value in Non-Smoking Females with Lung Adenocarcinoma by High-Throughput Sequencing.International journal of general medicine · 2023Article
- LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- miRNAs in Cancer (Review of Literature).International journal of molecular sciences · 2022Review
- MiR-582-3p participates in the regulation of biological behaviors of A549 cells by ambient PMEnvironmental science and pollution research international · 2022Article
- Hsa_circ_0020850 promotes the malignant behaviors of lung adenocarcinoma by regulating miR-326/BECN1 axis.World journal of surgical oncology · 2022Article
- Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.Cancer medicine · 2021Article
- From bulk, single-cell to spatial RNA sequencing.International journal of oral science · 2021Review
- Article
- Development and validation of an autophagy-related prognostic signature in esophageal cancer.Annals of translational medicine · 2021Article
- Comprehensive Analysis of a tRNA-Derived Small RNA in Colorectal Cancer.Frontiers in oncology · 2021Article
- Construction and validation of a novel prognostic signature of microRNAs in lung adenocarcinoma.PeerJ · 2021Article
- Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma.Computational and structural biotechnology journal · 2021Article
- Identification of plasma lipid species as promising diagnostic markers for prostate cancer.BMC medical informatics and decision making · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWe utilized miRNAs expression and clinical data to develop a prognostic signature for patients with lung adenocarcinoma, with respect to their overall survival, to identify high-risk subjects based on their miRNA genomic profile.
methodsMiRNA expressions based on miRNA sequencing and clinical data of lung adenocarcinoma patients (n = 479) from the Cancer Genome Atlas were randomly partitioned into non-overlapping Model (n = 320) and Test (n = 159) sets, respectively, for model estimation and validation.
resultsAmong the ten miRNAs identified using the univariate Cox analysis, six from miR-8, miR-181, miR-326, miR-375, miR-99a, and miR-10, families showed improvement of the overall survival chance, while two miRNAs from miR-582 and miR-584 families showed a worsening of survival chances. The final prognostic signature was developed with five miRNAs-miR-375, miR-582-3p, miR-326, miR-181c-5p, and miR-99a-5p-utilizing a stepwise variable selection procedure. Using the KEGG pathway analysis, we found potential evidence supporting their significance in multiple cancer pathways, including non-small cell lung cancer. We defined two risk groups with a score calculated using the Cox regression coefficients. The five-year survival rates for the low-risk group was approximately 48.76% (95% CI = (36.15, 63.93)); however, it was as low as 7.50% (95% CI = (2.34, 24.01)) for the high-risk group. Furthermore, we demonstrated the effect of the genomic profile using the miRNA signature, quantifying survival rates for hypothetical subjects in different pathological stages of cancer.
conclusionsThe proposed prognostic signature can be used as a reliable tool for identifying high-risk subjects regarding survival based on their miRNA genomic profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.